Koshi Kawakami

Koshi Kawakami

Auto-generated profile, based on publicly available information

Koshi Kawakami

Department of Oncology/Hematology, Shimane University Hospital, Izumo-shi, Shimane, Japan

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2015 in International Journal of Oncology
Verified
Journal Article
Open access
PDF file
TTTsutomu Takahashi
Tsutomu Takahashi
YHYoshio Honma
Yoshio Honma
TMTakaaki Miyake
Takaaki Miyake
KAKoji Adachi
Koji Adachi
STSaki Takami
Saki Takami
JSJunji Suzumiya
Junji Suzumiya
Multiple myeloma is a malignant proliferative disease of plasma cells in the bone marrow and remains largely incurable. Cotylenin A, a fusicoccane diterpene glycoside with a complex sugar moiety, was isolated as a plant-growth regulator. Cotylenin A has been shown to inhibit the growth of various cancer cells. Herein, we examined the anti-myeloma effects of cotylenin A using five human myeloma cell lines (RPMI-8226, KMS-11, KMS-26, KMS-12 PE and KMS-12 BM) and xenografts in immunodeficient mice. Cotylenin A and vincristine synergistically inhibited the growth and induced apoptosis in myeloma cells. While other microtubule-disturbing agents also showed co-operative effects with cotylenin A, other anticancer agents, such as doxorubicin, cisplatin, camptothecin, methotrexate, gemcitabine and 5-fluorouracil, did not show such co-operation with cotylenin A. These differences might be attributed to the effects on autophagic responses. Combined treatment with cotylenin A and vincristine induced autophagy (formation of LC3-II and degradation of p62 protein). However, doxorubicin did not enhance the autophagy induced by cotylenin A. A colony-forming assay indicated that the combined treatment with cotylenin A and vincristine more effectively suppressed the formation of large colonies, which have higher self-renewal activity than vincristine alone. Expression of pluripotency-associated transcription factor Sox2 mRNA in RPMI-8226 myeloma cells was significantly suppressed by treatment with cotylenin A. Combined treatment with cotylenin A and vincristine significantly inhibited the growth of KMS-26 myeloma cells as xenografts. Our results suggest that the combination of cotylenin A and vincristine may have therapeutic value. Recently, it was reported that cotylenin A modulates the 14-3-3 intracellular signaling pathway. The 14-3-3 proteins may be novel targets in treating myeloma. However, our study could not explain how the sensitization to vincristine is related to the effects of cotylenin A on the 14-3-3 signaling pathway and further studies will be needed.

22 February 2011 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
COChie Onishi
Chie Onishi
FIFumiyoshi Ikejiri
Fumiyoshi Ikejiri
KKKoshi Kawakami
Koshi Kawakami
TMTakaaki Miyake
Takaaki Miyake
SKSatoshi Kumanomido
Satoshi Kumanomido
JSJunji Suzumiya
Junji Suzumiya